Less invasive breast cancer surgery could reduce lymphedema risk

NCT ID NCT06092892

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether a less extensive lymph node surgery, called targeted axillary dissection (TAD), can safely control cancer in women aged 45 and older with early-stage ER+ breast cancer that has spread to lymph nodes detected by ultrasound. Participants will have breast surgery (lumpectomy or mastectomy) with TAD, followed by radiation therapy. The study will track how many women have cancer come back in the lymph nodes or breast over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Breast surgery (lumpectomy or mastectomy) with targeted axillary dissection and sentinel node biopsy, plus adjuvant radiation therapy

What this could lead to

If successful, this approach could offer a less invasive surgical option for women with early ER+ breast cancer that has spread to nearby lymph nodes, potentially reducing side effects like lymphedema.

What could go wrong

This is a small, early-phase trial with only 45 participants and no comparison group. It is not yet known if this approach is as effective as standard treatment, and there is a risk of cancer recurrence in the lymph nodes or breast.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm female breast carcinoma hormone receptor-positive breast cancer lymphedema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CS Cancer at Huntington Cancer Center

    RECRUITING

    Pasadena, California, 91105, United States

    Contact Phone: •••-•••-••••

    Contact

    Contact

    Contact

  • CS Cancer at Valley Oncology Medical Group

    RECRUITING

    Tarzana, California, 91356, United States

    Contact

    Contact Email: •••••@•••••

  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute

    RECRUITING

    Los Angeles, California, 90048, United States

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact